by Neoteryx, on October 2,2019
AUSTIN, TX – GX Sciences™ is now offering quick and easy blood analysis testing, known as Microsampling, through a unique Mitra® device, by Neoteryx. Blood Microsampling is an efficient and more simplified method of traditional …
Read Storyby Neoteryx, on March 21,2019
Dried blood samples can replace urine and hair monitoring for measuring more specific distinctions in alcohol consumption. TORRANCE, California – Neoteryx LLC is supplying its Volumetric Absorptive Microsampling (VAMS™) technology, in …
Read Storyby Neoteryx, on November 12,2018
UNITED KINGDOM and TORRANCE, CA – November 07, 2018 – Neoteryx, developer of microsampling devices with volumetric absorptive microsampling, is proud to supply its Mitra® devices to the Nottingham Pediatric …
Read Storyby Neoteryx, on August 16,2018
At-home blood sampling provides convenience and cost savings to patients. TORRANCE, California (August 16, 2018) – Neoteryx LLC, inventor of Volumetric Absorptive Microsampling (VAMS™) technology, has signed a research agreement …
Read Storyby Neoteryx, on July 18,2018
Dried blood samples replace urine monitoring for patients of alcohol and opioid addiction. TORRANCE, California – Today, Neoteryx LLC, announced that it will supply its Volumetric Absorptive Microsampling (VAMS™) technology, …
Read StoryThe latest product releases, company news and microsampling industry updates from Neoteryx.
If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com
Contact Us
Trajan Scientific Americas Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of blood. They are CE-IVD in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada and Ukraine.
In the USA, Mitra devices are supplied as a Research-Use Only (RUO) product, to assist in method development, other research-related and non-diagnostic activities. Mitra has not been validated for use with any diagnostic testing. The suitability of Mitra for any analytical application must be evaluated and validated by the laboratory or research institute in a manner consistent with local regulatory requirements.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use.
Mitra®, VAMS® & hemaPEN® are registered trademarks owned by entities in the Trajan Group.
Copyright © 2022. All rights reserved.